Ajanta Pharma - India Shines, Export Growth To Pick Up Ahead: Anand Rathi
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Anand Rathi Report
Ajanta Pharma Ltd.’s Q1 FY22 sales grew 11.9% to Rs 7.5 billion, driven by a rebound in India and strong growth in the U.S. and Africa branded segment.
The gross margin was flat at 77.1% YoY, while the Ebitda margin contracted 397 basis points to 29.4% as promotional costs are now surging to pre-Covid-19 levels.
Profit after tax grew 17.6% to Rs 1.7 billion due to a lower tax rate and forex gains.
Ajanta Pharma’s operations are now recovering from the impact of Covid-19 and the company has launched 25 products in India in the last one year while research and development spend for the U.S. has gone up.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.